Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2017 Oct 7;38(38):2879-2887.
doi: 10.1093/eurheartj/ehx350.

Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement

Adam Castaño  1   2 , David L Narotsky  1 , Nadira Hamid  3 , Omar K Khalique  3 , Rachelle Morgenstern  2 , Albert DeLuca  2 , Jonah Rubin  1 , Codruta Chiuzan  4 , Tamim Nazif  3 , Torsten Vahl  3 , Isaac George  3 , Susheel Kodali  3 , Martin B Leon  3 , Rebecca Hahn  3 , Sabahat Bokhari  2 , Mathew S Maurer  1
Affiliations
Comparative Study

Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement

Adam Castaño et al. Eur Heart J. .

Abstract

Aims: Transthyretin cardiac amyloidosis (ATTR-CA) has been reported in patients with aortic stenosis (AS) but its prevalence and phenotype are not known. We examine elderly patients with severe symptomatic AS undergoing transcatheter aortic valve replacement (TAVR) and determine the prevalence and phenotype of ATTR-CA non-invasively.

Methods and results: We performed technetium-99m pyrophosphate (99mTc-PYP) cardiac scintigraphy prospectively on patients who underwent TAVR, to screen for ATTR-CA. Transthoracic echocardiography and speckle-strain imaging were performed. We assessed the association of several parameters with ATTR-CA using multivariable logistic regression and constructed receiver operating curves to evaluate the best predictors of ATTR-CA. Among 151 patients (mean age 84 ± 6 years, 68% men), 16% (n = 24) screened positive for ATTR-CA with 99mTc-PYP scintigraphy. Compared with patients without ATTR-CA, ATTR-CA patients had a thicker interventricular septum (1.3 vs. 1.1 cm, P = 0.007), higher left ventricular (LV) mass index (130 vs. 98 g/m2, P = 0.002), and lower stroke volume index (30 vs. 36 mL/m2, P = 0.009). ATTR-CA patients had advanced diastolic dysfunction with higher E/A ratio (2.3 vs. 0.9, P = 0.001) and lower deceleration time (176 vs. 257 ms, P < 0.0001); impairment in systolic function with lower ejection fraction (48% vs. 56%, P = 0.011), myocardial contraction fraction (26 vs. 41, P < 0.0001), and average of lateral and septal mitral annular tissue Doppler S' (4.0 vs. 6.6 cm/s, P < 0.0001). While ATTR-CA patients had more impaired global longitudinal strain (-12 vs. -16%, P = 0.007), relative apical longitudinal strain was the same regardless of ATTR-CA diagnosis (0.98 vs. 0.98, P = 0.991). Average S' best predicted ATTR-CA in multivariable logistic regression (odds ratio 16.67 per 1 cm/s decrease with AUC 0.96, 95% confidence interval 0.90-0.99, P = 0.002) with a value ≤6 conferring 100% sensitivity for predicting a positive 99mTc-PYP amyloid scan.

Conclusions: Transthyretin cardiac amyloidosis is prevalent in 16% of patients with severe calcific AS undergoing TAVR and is associated with a severe AS phenotype of low-flow low-gradient with mildly reduced ejection fraction. Average tissue Doppler mitral annular S' of < 6 cm/s may be a sensitive measure that should prompt a confirmatory 99mTc-PYP scan and subsequent testing for ATTR-CA. Prospective assessment of outcomes after TAVR is needed in patients with and without ATTR-CA.

Keywords: Aortic stenosis; Low-flow low-gradient; Strain; TAVR; Transthyretin cardiac amyloidosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Predictors of ATTR-CA in elderly patients undergoing transcatheter aortic valve replacement. Quantitative assessment of technetium-99m pyrophosphate myocardial uptake (A) is shown in a patient with (bottom) and without ATTR-CA (top) with corresponding H/CL ratio. ROC curves for predictors of ATTR-CA (B). DT, deceleration time; H/CL, heart-to-contralateral ratio; MCF, myocardial contraction fraction; VMR, voltage-mass ratio; ATTR-CA, transthyretin cardiac amyloidosis.
Figure 2
Figure 2
Left ventricular geometry among patients undergoing transcatheter aortic valve replacement with and without ATTR-CA. P-value comparing patients with ATTR-CA vs. no ATTR-CA. ATTR-CA, transthyretin cardiac amyloidosis.
Figure 3
Figure 3
Speckle-strain imaging in elderly patients with severe symptomatic AS with and without ATTR-CA. Bullseye plots demonstrate relative apical sparing is the same whether amyloid is present or not. AS, aortic stenosis; ATTR-CA, transthyretin cardiac amyloidosis.
Figure 4
Figure 4
Prevalence and phenotype of ATTR-CA among patients undergoing transcatheter aortic valve replacement at our institution. ATTR-CA, transthyretin cardiac amyloidosis.
See this image and copyright information in PMC

Comment in

References

    1. Thaden JJ, Nkomo VT, Enriquez-Sarano M.. The global burden of aortic stenosis. Prog Cardiovasc Dis 2014;56:565–571. - PubMed
    1. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Lung B, Lancellotti P, Pierard L, Price S, Schafers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M; ESC Committee for Practice Guidelines (CPG); Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology; European Association for Cardio-Thoracic Surgery. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 2012;42:S1–S44. - PubMed
    1. Clark MA, Arnold SV, Duhay FG, Thompson AK, Keyes MJ, Svensson LG, Bonow RO, Stockwell BT, Cohen DJ.. Five-year clinical and economic outcomes among patients with medically managed severe aortic stenosis results from a medicare claims analysis. Circ-Cardiovasc Qual 2012;5:697–704. - PubMed
    1. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, O’Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM 3rd, Thomas JD; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:e57–e185. - PubMed
    1. Dayan V, Vignolo G, Magne J, Clavel MA, Mohty D, Pibarot P.. Outcome and impact of aortic valve replacement in patients with preserved LVEF and low-gradient aortic stenosis. J Am Coll Cardiol 2015;66:2594–2603. - PubMed

Publication types

MeSH terms

Substances

Supplementary concepts